Commit Biologics Breakthrough: Enhancing Immunotherapy with Novel Complement Engager Platform Commit Biologics announces promising results from its Complement Engager platform in NHPs, demonstrating fast, effective immune cell depletion with a safe profile.

Commit Biologics Breakthrough: Enhancing Immunotherapy with Novel Complement Engager Platform #Denmark #Aarhus #Commit_Biologics #Complement_Engager #BiCE™

Commit Biologics Enhances Its BiCE Technology Through Strategic Scientific Advisory Board Invitation Commit Biologics has established a new Scientific Advisory Board, featuring renowned experts to advance its BiCE technology platform aimed at treating autoimmune diseases and cancer.

Commit Biologics Enhances Its BiCE Technology Through Strategic Scientific Advisory Board Invitation #Denmark #Aarhus #Commit_Biologics #Scientific_Advisory_Board #BiCE_Technology

Commit Biologics Secures €5.5 Million Investment for Innovative Cancer Therapy Development Commit Biologics announces a €5.5 million investment from Korys, enhancing their groundbreaking BiCE™ platform for cancer treatment with ambitious goals.

Commit Biologics Secures €5.5 Million Investment for Innovative Cancer Therapy Development #Denmark #Aarhus #Commit_Biologics #BiCE #Korys

Commit Biologics Welcomes Dr. Janine Schuurman to Its Board for Advancing Antibody Technology Commit Biologics has announced the appointment of Dr. Janine Schuurman to its Board of Directors, emphasizing advancements in antibody technology and drug development.

Commit Biologics Welcomes Dr. Janine Schuurman to Its Board for Advancing Antibody Technology #Denmark #Aarhus #Janine_Schuurman #Commit_Biologics #BiCE_Platform